Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Applied Materials
  4. Fast Track Articles
  5. Fast Track Article
image of Formulation, Optimization, and Evaluation of Solid-lipid Formulation for Bioavailability Enhancement Utilizing Diltiazem Hydrochloride

Abstract

Background

Cardiac arrhythmia is a health concern, requiring effective medication for proper treatment. Diltiazem hydrochloride (DTZ.HCL), a class IV anti-arrhythmic calcium channel blocker, was used as a model drug due to its ability to block Ca++ channels in the SA and AV nodes, reducing calcium entry into cardiac cells and subsequently decreasing the force of contraction and oxygen consumption by the heart. Despite its good oral absorption, DTZ.HCL bioavailability is reduced to approximately 40% due to extensive first-pass metabolism. A nano-enabled drug delivery system has the advantage of incorporating both lipophilic and hydrophilic drugs with improved physical stability and enhanced bioavailability.

Objective

The objective of this study was to develop a solid-lipid formulation utilizing diltiazem hydrochloride and evaluate it for its bioavailability enhancement.

Method

In the experimental study, SLNs were prepared using the microemulsion technique. A blend ratio (1:1) of lipid (stearic acid: compritol 888 ATO), span 80, PEG 200, and water was selected based on the microemulsion region obtained from the Triplot (4.1) ternary phase diagram. The hydrophilic drug diltiazem hydrochloride was incorporated into the lipid blend, and a preheated Smix was maintained at 80°C to obtain a transparent microemulsion, which then crystallized to form SLNs upon subsequent dispersion in cold water (1:25). Critical process parameters, including magnetic stirring speed, homogenizer speed, and probe sonication cycle, were optimized using Design Expert 10 software to achieve the desired particle size diameter, PDI, and entrapment efficiency.

Results

The results revealed that the particle size and PDI were significantly influenced by the span 80 and PEG 200. An increase in the concentration of the lipid blend resulted in large particle sizes. The optimized formulation showed a particle size of 415.4±0.2 nm, PDI of 0.184±0.01, and zeta potential of -24.19±0.12 mV. These results were corroborated by DSC thermograms, which indicated reduced enthalpy associated with the reduced particle size of SLNs. Given that diltiazem hydrochloride is a hydrophilic drug with high water solubility, the entrapment efficiency was relatively 30.6% ±0.45. release studies demonstrated an initial burst release, followed by a sustained release of 85% over 24 hours. The optimized SLNs followed the Higuchi matrix model, with a coefficient of correlation (R2) value of 0.9369.

Conclusion

Results concluded successful development of SLNs with improved bioavailability when compared by way of method with marketed preparations.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cam/10.2174/0126667312325351241009063848
2024-10-17
2024-11-23

  • From This Site

    /content/journals/cam/10.2174/0126667312325351241009063848
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Jaye D.A. Xiao Y. Sigg D.C. Cardiac Electrophysiology Meth-ods and Models. Cham Springer 2010 41 52 [http://dx.doi.org/10.1007/978-1-4419-6658-2_2]
    [Google Scholar]
  2. Durham D. Worthley L.I.G. Cardiac arrhythmias: Diagnosis and management. The tachycardias. Crit. Care Resusc. 2002 4 1 35 53 [http://dx.doi.org/10.1016/S1441-2772(23)00717-2]. [PMID: 16573402].
    [Google Scholar]
  3. Buckley M.M.T. Grant S.M. Goa K.L. McTavish D. Sorkin E.M. Diltiazem. Drugs 1990 39 5 757 806 [http://dx.doi.org/10.2165/00003495-199039050-00009]. [PMID: 2191851].
    [Google Scholar]
  4. Kendall M.J. Okopski J.V. Calcium antagonism--with special reference to diltiazem. J. Clin. Pharm. Ther. 1986 11 3 159 174 [http://dx.doi.org/10.1111/j.1365-2710.1986.tb00841.x]. [PMID: 3528227].
    [Google Scholar]
  5. Tripathi KD Essentials of medical pharmacology. 2008
    [Google Scholar]
  6. Mandawgade S.D. Patravale V.B. Development of SLNs from natural lipids: Application to topical delivery of tretinoin. Int. J. Pharm. 2008 363 1-2 132 138 [http://dx.doi.org/10.1016/j.ijpharm.2008.06.028]. [PMID: 18657601].
    [Google Scholar]
  7. Müller R.H. Radtke M. Wissing S.A. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv. Drug Deliv. Rev. 2002 54 Suppl. 1 S131 S155 [http://dx.doi.org/10.1016/S0169-409X(02)00118-7]. [PMID: 12460720].
    [Google Scholar]
  8. Huo J. Zhou S. New research on development of solid lipid nanoparticles. J. Med. Coll. PLA 2007 22 6 385 390 [http://dx.doi.org/10.1016/S1000-1948(08)60023-4].
    [Google Scholar]
  9. Lim S.B. Banerjee A. Önyüksel H. Improvement of drug safety by the use of lipid-based nanocarriers. J. Control. Release 2012 163 1 34 45 [http://dx.doi.org/10.1016/j.jconrel.2012.06.002]. [PMID: 22698939].
    [Google Scholar]
  10. Naseri N. Valizadeh H. Zakeri-Milani P. Solid lipid nanopar-ticles and nanostructured lipid carriers: Structure, preparation and application. Adv. Pharm. Bull. 2015 5 3 305 313 [http://dx.doi.org/10.15171/apb.2015.043]. [PMID: 26504751].
    [Google Scholar]
  11. Müller R.H. Mäder K. Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur. J. Pharm. Biopharm. 2000 50 1 161 177 [http://dx.doi.org/10.1016/S0939-6411(00)00087-4]. [PMID: 10840199].
    [Google Scholar]
  12. Yadav N. Khatak S. Singh Sara U.V. Solid lipid nanoparticles- A review. Int J Appl Pharm 2013 5 2 8 18
    [Google Scholar]
  13. Anurak L. Chansiri G. Peankit D. Somlak K. Griseofulvin solid lipid nanoparticles based on microemulsion technique. Adv. Mat. Res. 2011 197-198 47 50 [http://dx.doi.org/10.4028/www.scientific.net/AMR.197-198.47].
    [Google Scholar]
  14. Negi J.S. Chattopadhyay P. Sharma A.K. Ram V. Development of solid lipid nanoparticles (SLNs) of lopinavir using hot self nano-emulsification (SNE) technique. Eur. J. Pharm. Sci. 2013 48 1-2 231 239 [http://dx.doi.org/10.1016/j.ejps.2012.10.022]. [PMID: 23153618].
    [Google Scholar]
  15. Ghadiri M. Fatemi S. Vatanara A. Loading hydrophilic drug in solid lipid media as nanoparticles: Statistical model-ing of entrapment efficiency and particle size. Int. J. Pharm. 2012 424 1-2 128 137 [http://dx.doi.org/10.1016/j.ijpharm.2011.12.037]. [PMID: 22227603].
    [Google Scholar]
  16. Prabhakar K. Afzal S.M. Surender G. Kishan V. Tween 80 containing lipid nanoemulsions for delivery of indinavir to brain. Acta Pharm. Sin. B 2013 3 5 345 353 [http://dx.doi.org/10.1016/j.apsb.2013.08.001].
    [Google Scholar]
  17. Das S. Chaudhury A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS PharmSciTech 2011 12 1 62 76 [http://dx.doi.org/10.1208/s12249-010-9563-0]. [PMID: 21174180].
    [Google Scholar]
  18. Shukla S. Pandit V. Trojan Microparticles: A Composite Nanoparticle Delivery System. Curr. Drug Ther. 2024 19 4 413 425 [http://dx.doi.org/10.2174/1574885518666230726142855].
    [Google Scholar]
  19. Kaur I.P. Bhandari R. A method to prepare solid lipid nano-particles with improved entrapment efficiency of hydrophilic drugs. Curr. Nanosci. 2013 9 2 1 10
    [Google Scholar]
  20. Kakkar V. Kaur I.P. Preparation, characterization and scale-up of sesamol loaded solid lipid nanoparticles. Nanotechnol Devel 2012 2 1 8 [http://dx.doi.org/10.4081/nd.2012.e8].
    [Google Scholar]
  21. Aburahma M.H. Badr-Eldin S.M. Compritol 888 ATO: A multifunctional lipid excipient in drug delivery systems and nanopharmaceuticals. Expert Opin. Drug Deliv. 2014 11 12 1865 1883 [http://dx.doi.org/10.1517/17425247.2014.935335]. [PMID: 25152197].
    [Google Scholar]
  22. Bhoop B.S. Quality by design (QbD) for holistic Pharma excellence and regulatory compliance. Pharm. Times 2014 46 8 26 33
    [Google Scholar]
  23. Singh B. Kapil R. Nandi M. Ahuja N. Developing oral drug delivery systems using formulation by design: Vital precepts, retrospect and prospects. Expert Opin. Drug Deliv. 2011 8 10 1341 1360 [http://dx.doi.org/10.1517/17425247.2011.605120]. [PMID: 21790511].
    [Google Scholar]
  24. Singh B Kapil R Bandyopadhyay S Ahuja N Drug delivery optimization using experimental designs. 2023
    [Google Scholar]
  25. Singh B. Dahiya M. Saharan V. Ahuja N. Optimizing drug delivery systems using systematic “design of experiments.” Part II: Retrospect and prospects. Crit. Rev. Ther. Drug Carrier Syst. 2005 22 3 215 294 [http://dx.doi.org/10.1615/CritRevTherDrugCarrierSyst.v22.i3.10]. [PMID: 15896189].
    [Google Scholar]
  26. Singh S. Dobhal A.K. Jain A. Pandit J.K. Chakraborty S. For-mulation and evaluation of solid lipid nanoparticles of a wa-ter soluble drug: Zidovudine. Chem. Pharm. Bull. (Tokyo) 2010 58 5 650 655 [http://dx.doi.org/10.1248/cpb.58.650]. [PMID: 20460791].
    [Google Scholar]
  27. Pooja D. Tunki L. Kulhari H. Reddy B.B. Sistla R. Optimiza-tion of solid lipid nanoparticles prepared by a single emulsi-fication-solvent evaporation method. Data Brief 2015 6 6 15 19 [PMID: 26759823].
    [Google Scholar]
  28. Siewert M. Dressman J. Brown C.K. FIP/AAPS guide-lines to dissolution/in vitro release testing of novel/special dosage forms. AAPS PharmSciTech 2003 4 1 43 52 [http://dx.doi.org/10.1208/pt040107]. [PMID: 12916916].
    [Google Scholar]
  29. Venkateswarlu V. Manjunath K. Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanopar-ticles. J. Control. Release 2004 95 3 627 638 [http://dx.doi.org/10.1016/j.jconrel.2004.01.005]. [PMID: 15023472].
    [Google Scholar]
  30. Sangsen Y. Likhitwitayawuid K. Sritularak B. Wiwattana-wongsa K. Wiwattanapatapee R. Novel solid lipid nanoparti-cles for oral delivery of oxyresveratrol: Effect of the formu-lation parameters on the physicochemical properties and in vitro release. Int. J. Pharm. 2013 7 877 884
    [Google Scholar]
  31. Nappinnai M. Kishore V.S. Formulation and evaluation of microspheres of diltiazem hydrochloride. Indian J. Pharm. Sci. 2007 69 4 511 515 [http://dx.doi.org/10.4103/0250-474X.36935].
    [Google Scholar]
  32. Akifuddin S K Abbas Z 2013
/content/journals/cam/10.2174/0126667312325351241009063848
Loading
Formulation, Optimization, and Evaluation of Solid-lipid Formulation for Bioavailability Enhancement Utilizing Diltiazem Hydrochloride
Bentham Science Publishers ; https://doi.org/10.2174/0126667312325351241009063848
/content/journals/cam/10.2174/0126667312325351241009063848
/content/journals/cam/10.2174/0126667312325351241009063848
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: microemulsion ; entrapment efficiency ; pseudoternary phase diagram ; Bioavailability ; solid lipid nanoparticles

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test